Researchers tested the new medicine in a one-year study of 17000 patients in the state of Acre in the Brazilian Amazon. Health care resources in the area were also expanded, including early identification of malaria. Health officials say the result was a 36% drop in cases.

 研究者在为期一年的17000位巴西亚马逊Acre州病身人上测试了这个新药品。当地的健康照料资源也在被发展，包括早期疟疾的识别。健康官员表示，结果使发病率下降了36%。

Malaria is caused by a parasite which is passed to humans though mosquito bites. As many as 500 million infections happen every year. Around 60% of the cases, and more than 80% of the deaths, happen in Africa south of the Sahara. Africa suffers more than a million deaths, mostly children.

 痢疾是通过蚊虫叮咬将寄生虫传播到人体的疾病。 每年有高达5亿例发生。其中的60%以及超过80%的死亡发生在非洲撒哈拉南部。非洲每年有100多万人死亡，大部分为儿童。

Doctor Pecoul says his organization is supporting a study in Tanzania to see if the new drug could be used successfully in Africa. Currently in Africa, there are two first-line treatments with artesunate and other drugs. He says artesunate and mefloquine could have a use in places like eastern Africa where there are high levels of resistance to several drugs.

 Pecoul医生说他的组织正在支持坦桑尼亚的一个研究，该研究在试验这种新药能否在非洲使用。目前非洲治疗的首选药不是artesunate和其它药物。他说artesunate和mefloquine可以在一些地方使用，例如东非，这里的病人对一些药有很高的抗药性。

The Drugs for Neglected Diseases Initiative began in 2003. It was established by the Pasteur Institute and Doctors without Borders along with four publicly supported research organizations.

 被忽略疾病药物组织建于2003年。它是由巴斯德研究所和医生无国界组织以及其它4个公共自主研究组织共同建立的。

posted on 2008-05-02 08:38 BL 阅读(29) 评论(0)  编辑  收藏 网摘收藏